An Open Label Phase Ib Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Maximum Tolerated Dose of Anetumab Ravtansine in Combination With Pemetrexed 500 mg/m2 and Cisplatin 75 mg/m2 in Subjects With Mesothelin-expressing Predominantly Epithelial Mesothelioma or Nonsquamous Non-small-cell Lung Cancer

Trial Profile

An Open Label Phase Ib Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Maximum Tolerated Dose of Anetumab Ravtansine in Combination With Pemetrexed 500 mg/m2 and Cisplatin 75 mg/m2 in Subjects With Mesothelin-expressing Predominantly Epithelial Mesothelioma or Nonsquamous Non-small-cell Lung Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Dec 2017

At a glance

  • Drugs Anetumab ravtansine (Primary) ; Cisplatin (Primary) ; Pemetrexed (Primary)
  • Indications Mesothelioma; Non-small cell lung cancer
  • Focus Adverse reactions
  • Sponsors Bayer
  • Most Recent Events

    • 29 Nov 2017 Planned End Date changed from 31 Jul 2018 to 28 Feb 2019.
    • 29 Nov 2017 Planned primary completion date changed from 28 May 2018 to 18 May 2018.
    • 30 Oct 2017 Results (as of June 12, 2017) assessing safety, tolerability, and maximum tolerated dose (MTD) presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top